Amol Akhade/hiranandanihospital.org
Sep 9, 2025, 15:49
Amol Akhade: EA5181 Trial Results in Unresectable Stage III NSCLC
Amol Akhade, Senior Consultant at Fortis Hospitals Mumbai, shared a post on X:
“EA5181 Trial
In unresectable stage III NSCLC, adding concurrent durvalumab to CRT (vs CRT alone → durva consolidation) showed:
- No OS benefit – HR 1.03 (95% CI 0.80–1.32)
- No PFS benefit – HR 1.05 (95% CI 0.86–1.29)
- No change in recurrence or ORR
- PACIFIC remains the standard: CRT 1 yr durvalumab consolidation.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 9, 2025, 15:59
Sep 9, 2025, 15:49
Sep 9, 2025, 15:46
Sep 9, 2025, 15:42
Sep 9, 2025, 15:28